Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Substance Patent for Therapeutic Protein Delivery Allowed in US: NanoCarrier
December 14, 2011
- PI/II Results Confirm Safety, Tolerability of Oral Proteasome Inhibitor: Takeda
December 14, 2011
- 86% of Patients Show Objective Responses in PII Trial of CD30 Monoclonal Antibody: Takeda
December 14, 2011
- Mochida Pharmaceutical Grants Rights for Diabetes Treatment to US Merck
December 13, 2011
- Kissei Pharmaceutical to Transfer Marketing Rights for CABASER to Pfizer Japan
December 13, 2011
- Otsuka's US Subsidiary CEO to Become New President, Taiho Pharmaceutical
December 13, 2011
- Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision
December 13, 2011
- Ohara Pharmaceutical to Initiate Clinical Trials for Leukemia Treatment Drug Requested for Development
December 13, 2011
- OncoTherapy’s Subsidiary Immunas Receives Milestone Payment from Kyowa Hakko Kirin
December 13, 2011
- EC Grants Marketing Authorization for Takeda’s ARB Edarbi
December 12, 2011
- Fuso Withdraws NDA for PHN Treatment in Japan, Prepares for Additional Studies
December 12, 2011
- Will Ilaris Remain an “Ultra-orphan” Drug?
December 10, 2011
- DODA Survey Shows MR’s Average Annual Income at ¥6.61 Million, 6th Highest by Occupation
December 9, 2011
- GSK’s Ofatumumab and Pazopanib Granted Orphan Drug Designation
December 9, 2011
- Kyowa Kirin Aims to Make RNAi Drugs Future Pillar: Dr Shitara
December 9, 2011
- Kobayashi, President of Mitsubishi Chemical HD Expects Continuous Growth of Pharmaceutical Business
December 9, 2011
- Takeda Says FDA Committee Indicates Recommendation for Peginesatide
December 9, 2011
- Shionogi Announces Favorable Decision in Fortamet Preliminary Injunction Proceedings
December 9, 2011
- MTPC Sets Up External Committee to Promote Appropriate Use of Telavic
December 8, 2011
- Mebiopharm, Nawaloka HD to Establish Joint Venture in Sri Lanka
December 8, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…